Connor Iapoce

Although sharing a common feature of male predominance, alopecia did not seem to occur more frequently in AS patients.

45% of study participants were either dissatisfied or very dissatisfied with their current medical treatment.

Mean age of hypertension diagnosis was 4 - 5 years earlier among Black and Hispanic adults vs White adults between 2011 and 2020.

The biosimilar product was deemed interchangeable with ranibizumab injection across all five retinal indications.

Study data show 14% of eyes managed with intravitreal therapy in routine clinical care experienced ≥ 10 letter loss.

Dapagliflozin consistently reduced the risk of CV death or HHF, HHF alone, and progression of kidney disease regardless of background use of CV medications, investigators say.

Cross-sectional data suggest a discontinuity in endothelial cell–density measurements just below 2500 cells.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM utilization decreased with increasing age in older adulthood.

The increase does not appear to have a negative impact on post transplant survival, investigators say.

New data report a slightly higher but nonsignificant increase in diabetes incidence among children in Canada during COVID-19 pandemic.

The worldwide burden of vision loss continues to climb, but there may be solutions with regards to better access to care and improved screening.

This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.

Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

The NDA was granted Priority Review designation with a PDUFA target action date of November 26, 2022.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.

More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.